Patient | Sex | Age | Stage | Site of metastasis | Previous therapies (drug) | Enrolled | Vaccine treatment | OR | TTP (months) | Overall survival (months) |
---|---|---|---|---|---|---|---|---|---|---|
1 | F | 71 | IIIC | Skin recurrence | None | Yes | Complete | SD | 7 | 34 |
2 | F | 47 | IV | Lung, lymphonodal | 2 (DTIC, Vemurafenib) | Yes | 2 injections | PD | 2 | 2 |
3 | M | 73 | IV | Skin lymphnodal, liver | 3 (DTIC, Vemurafenib, Ipilimumab) | Yes | Complete | SD | 26 | 31 |
4 | M | 38 | IV | Lymphonodal, lung | 1(Vemurafenib) | Yes | 2 injections | PD | 2 | 5 |
5 | M | 66 | IV | Lung, lymphonodal | 3 (DTIC-IL2, BOLD, Ipilimumab) | Yes | Complete | SD | 5 | 9 |
6 | F | 68 | IV | Skin, lung, lymphonodal | 2 (DTIC, Ipilimumab | Yes | No injection | NA | NA | NA |
7 | F | 63 | IV | Adrenal, lymphonodal | none | No | ||||
8 | M | 69 | IV | Brain, lymphonodal, lung, bone | 3(Fotemustine, Ipilimumab, DTIC) | No | ||||
9 | F | 51 | IV | Brain, lung, lymphonodal, spleen | 5 (DTIC, Fotemustine, Paclitaxel, Ipilimumab, Dabrafenib | No | ||||
10 | M | 66 | IV | Lung, lymphonodal, spleen | 4 (DTIC+ Bevacizumab, Fotemustine, CDDP + Paclitaxel, Ipilimumab) | No |